Quantcast

Latest Prostate cancer Stories

2014-10-22 16:27:57

With a device necessary for many medical conditions and surgeries, manufacturers of urinary catheters have a safe and stable source of revenue that can withstand the steepest of economic downturns. VANCOUVER, Oct. 22, 2014 /PRNewswire/ - According to in-depth reports from iData Research, the leading global authority on medical device market research, the combined U.S. and European markets for urological devices was valued at almost US$4.7 billion in 2013, with both Coloplast and...

2014-10-22 08:27:56

NEW YORK, Oct. 22, 2014 /PRNewswire/ -- New test innovations will be the source of revenue growth in the in vitro diagnostic (IVD) test industry, especially as companies struggle with reimbursement challenges, according to Kalorama Information. The healthcare market researcher listed more than 25 testing innovations in important disease areas in academic settings that could be the future of IVD products. Kalorama details the new approaches its biennial survey of the IVD industry, The...

2014-10-21 08:34:00

NEW YORK, Oct. 21, 2014 /PRNewswire/ -- Honoring one's Hispanic heritage is about more than just celebrating your roots, it is about bringing awareness of issues that affect your community. Prostate cancer is the most common cancer among Hispanic man, affecting 1-in-7 during their lifetime. Dr. David Samadi, chief of urology at Lennox Hill Hospital in New York City, is urging Latin women to have the men in their lives get a simple blood test as a way to screen their prostate health....

2014-10-20 08:33:28

Funds to Support Commercial Expansion in the U.S. and International Launch of the Veran Thoracic Navigation System(TM) ST. LOUIS, Mo., Oct. 20, 2014 /PRNewswire/ -- Veran Medical Technologies, a market leader in thoracic navigation for early detection of lung cancer, announced today the completion of a $12M financing to support the Company's continued commercial expansion in the U.S. and international launch of the Veran Thoracic Navigation System(TM). A strong syndicate of private...

2014-10-18 12:20:54

Treatments at Scripps Proton Therapy Center enable Scott to continue collegiate coaching SAN DIEGO, Oct. 18, 2014 /PRNewswire/ -- Steve Scott became one of the greatest mile runners in American history by taking a strategic approach to his craft. To view the multimedia assets associated with this release, please click: http://www.multivu.com/players/English/7350051-scripps-health-steve-scott-reveals-proton-treatments-for-prostate-cancer/ "I surrounded myself with the best...

2014-10-17 00:21:14

SAN DIEGO, Oct. 16, 2014 /PRNewswire/ -- GenomeDx Biosciences today announced that a draft local coverage determination (LCD) for its Decipher® Prostate Cancer Classifier has been published by the Centers for Medicare and Medicaid Services (CMS) describing a coverage and payment policy for use of the Decipher test in men who have undergone radical prostatectomy. An LCD is a decision by Medicare contractors to cover an item or service. Decipher is the only genomic test for prostate...

2014-10-16 08:30:32

NEW YORK, Oct. 16, 2014 /PRNewswire/ -- Analyst Report by Small Cap IR. Actinium Pharmaceuticals, Inc. (NYSE: ATNM) - According to the World Health Organization, over 14 million new cases of cancer are reported each year, and cancer cases are expected to surge 57% worldwide over the next 20 years. The fastest growing hospital treatment in the United States to treat this disease is Hematopoietic Stem Cell Transplantation; the transplantation of multipotent hematopoietic stem cells...

2014-10-14 12:30:37

OWINGS MILLS, Md., Oct. 14, 2014 /PRNewswire-USNewswire/ -- Chesapeake Urology Associates ("Chesapeake"), continually on the forefront of clinical and technological innovation, offers a state-of-the-art prostate cancer diagnostic, which "fuses" detailed MRI scans with live, real-time ultrasound images of the prostate. This groundbreaking biopsy system provides Chesapeake urologists with the capability to pinpoint tumors within the prostate gland, leading to more targeted treatment planning...

2014-10-14 12:29:42

WASHINGTON, Oct. 14, 2014 /PRNewswire-USNewswire/ -- ZERO - The End of Prostate Cancer recently awarded the Jim Lafferty Memorial Research Grant in the amount of $45,000 to Peter Carroll, M.D., M.P.H., of UC San Francisco for the purpose of researching new and improved methods for early detection of prostate cancer. The grant is part of the ZERO Cancer Research Fund, charged with supporting innovative, high-reward research that offers the best return on investment for patients and...

2014-10-14 08:34:17

First Patient Has Begun Treatment Process; Additional Patients Being Assessed; Waiting List Established BETHESDA, Md., Oct. 14, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the DCVax-L Hospital Exemption Program that was approved by the German regulatory authority earlier this year is now under way. The first patient with Glioblastoma...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.